What Mounjaro Can Cause: Side Effects, Risks and When to Act

Step 1: what happens in the first few weeks

When you begin tirzepatide at the 2.5 mg starting dose, your body is adjusting to a medicine that slows how quickly your stomach empties and signals satiety through two gut-hormone pathways simultaneously. That adjustment period is where most side effects concentrate. Nausea is the most commonly reported experience, followed by loose stools or constipation, burping, reflux and a general feeling of fullness that can make it hard to eat normally.

One misconception worth addressing gently: many people assume feeling sick means the medicine is damaging them. For most, it reflects the stomach adjusting to a slower emptying rate, not injury. The NHS tirzepatide medicines page lists these effects and notes they are usually mild to moderate. Headache, fatigue and dizziness also appear on that list and are worth knowing about if you are driving or operating machinery in the early weeks.

Injection-site reactions (redness, itching or a small lump at the injection site) are less discussed but real. Rotating between the abdomen, thigh and upper arm helps reduce this. If you are reading more about whether to begin treatment, the page on what to expect when you start Mounjaro covers the practical side of those early weeks in more detail.

Step 2: effects that can arise as the dose increases

Titration, the process of moving from one dose to the next roughly every four weeks, is when side effects can resurface briefly. Each increase asks the digestive system to adapt again. This is why the schedule exists and why a prescriber rather than the patient decides the timing.

Gallbladder problems, including gallstones, are a known effect of rapid weight loss itself and of GLP-1 class medicines. Symptoms to recognise include sudden pain in the upper right abdomen, pain spreading to the shoulder, and nausea alongside it. These need medical assessment rather than waiting to see if they settle.

Dehydration is an under-discussed risk. If vomiting or diarrhoea is persistent enough to reduce fluid intake significantly, kidney function can be affected. Staying well-hydrated is straightforward advice but genuinely important on this treatment. The Mounjaro overview page has a broader look at how the medicine works and what the clinical trial programme found.

Low mood and, in rare cases, thoughts of self-harm have been flagged in post-marketing surveillance for GLP-1 medicines. This is an area of ongoing monitoring rather than established causation, but it is worth telling your prescriber if your mental state changes during treatment.

Step 3: serious effects that need urgent attention

Most people tolerate Mounjaro well. Serious effects are uncommon. That said, they exist and it is worth knowing which symptoms should prompt same-day medical contact or a call to 999 rather than a wait-and-see approach.

Acute pancreatitis sits at the top of that list. In January 2026, the MHRA issued a Drug Safety Update for GLP-1 receptor agonists specifically calling out acute pancreatitis as an infrequent but potentially serious adverse effect. The signal: severe, persistent pain in the stomach area that extends toward the back, with or without vomiting. Stop eating, stop the injection, and get medical help without delay.

Allergic reactions, though rare, can include swelling of the face, lips or throat, difficulty breathing and a widespread rash. These are emergencies. A localised skin reaction where the needle goes in is very different from a systemic allergic response. Tirzepatide has also been associated with changes in heart rate; if you notice a consistently faster pulse at rest, mention it at your next clinical review.

There are also questions patients sometimes raise about less expected effects. Whether Mounjaro can cause something like deep vein thrombosis or a skin rash gets a more detailed look in the dedicated pages for those topics, worth reading if either is on your mind.

Step 4: who is at higher risk and what the prescriber weighs up

Certain health histories make some of these effects more likely or more serious. A personal or family history of medullary thyroid carcinoma, or a condition called MEN2, rules out tirzepatide entirely. A history of pancreatitis or severe gastrointestinal conditions (including gastroparesis) requires a careful prescriber conversation before treatment begins.

Questions also come up about effects on other body systems. There is a dedicated page looking at the evidence around Mounjaro and multiple sclerosis, and another examining how tirzepatide interacts with IBS, for anyone navigating those specific concerns.

For women using oral contraceptives, tirzepatide can reduce pill absorption in the first four weeks of treatment and for four weeks after each dose increase, a non-oral method should be added during those windows. If you are considering cost alongside safety when thinking about treatment, the guide to Mounjaro pricing in the UK puts the market context plainly.

Every person's risk profile is different. That is precisely why a GPhC-registered prescriber reads your full clinical picture before any treatment is approved, and why the same review happens before each repeat. If any of this has raised questions specific to your situation, a free consultation with our clinical team is a good place to start.